Evidence map›Paper›PMID 39340002›Full record

ArticleVaccines2024

Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection.

Whitney C Weber, Takeshi F Andoh, Craig N Kreklywich, Zachary J Streblow, Michael Denton, Magdalene M Streblow, John M Powers, Gauthami Sulgey, Samuel Medica, Igor Dmitriev and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Whitney C WeberVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-5868-8085
Takeshi F AndohVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Craig N KreklywichVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Zachary J StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Michael DentonVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Magdalene M StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
John M PowersVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-0485-9109
Gauthami SulgeyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0009-0006-1015-7281
Samuel MedicaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Igor DmitrievCancer Biology Division, Department of Radiation Oncology, Washington University, St. Louis, MO 63110, USA.ORCID 0000-0001-9206-1975
David T CurielCancer Biology Division, Department of Radiation Oncology, Washington University, St. Louis, MO 63110, USA.ORCID 0000-0003-3802-6014
Nicole N HaeseVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Daniel N StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-6828-2492

Funding

NIH HHS 1R41AI038964-18A1
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for use. Mayaro virus (MAYV) is a related emerging alphavirus with epidemic potential with circulation overlap potential with CHIKV. We previously reported the ability of a non-replicating human adenovirus (AdV)-vectored vaccine expressing the MAYV structural polyprotein to protect against disease in mice following challenge with MAYV, CHIKV and UNAV. Herein, we evaluated mouse immunity and protective efficacy for an AdV-CHIKV full structural polyprotein vaccine in combination with heterologous AdV-MAYV prime/boost regimens versus vaccine coadministration. Heterologous prime/boost regimens skewed immunity toward the prime vaccine antigen but allowed for a boost of cross-neutralizing antibodies, while vaccine co-administration elicited robust, balanced responses capable of boosting. All immunization strategies protected against disease from homologous virus infection, but reciprocal protective immunity differences were revealed upon challenge with heterologous viruses. In vivo passive transfer experiments reproduced the inequity in reciprocal cross-protection after heterologous MAYV challenge. We detected in vitro antibody-dependent enhancement of MAYV replication, suggesting a potential mechanism for the lack of cross-protection. Our findings provide important insights into rational alphavirus vaccine design that may have important implications for the evolving alphavirus vaccine landscape.

Indexed as

alphavirusesantibodyChikungunya virus (CHIKV)cross-neutralizationMayaro virus (MAYV)vaccine

Identifiers

PMID39340002
PMCPMC11435824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.